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Abstract 
Chronic myelogenous leukemia (CML) stem cells (LSC) are responsible for initiating and 
maintaining clonal hematopoiesis. These cells persist in the bone marrow (BM) despite effective 
inhibition of the BCR-ABL kinase activity by tyrosine kinase inhibitors (TKI). Here, we show that 
miR-126 supports quiescence, self-renewal and engraftment capacity of CML LSC. However, 
despite this key role, endogenous miR-126 is decreased in CML LSC compared to the normal 
counterpart of long-term hematopoietic stem cells (LTHSC), through a BCR-ABL-dependent 
mechanism involving interactions between phosphorylated-SPRED1 and RAN, inhibition of the 
RAN/EXP-5/RCC1 complex, and subsequent interference of mature miR-126 biogenesis. 
Endothelial cells (EC) in the BM then supply miR-126 to CML LSC to support quiescence and 
leukemia growth as we showed using genetic CML models with conditional miR-126 knock-out 
(KO) in EC and/or LSC. Notably, by inhibiting BCR-ABL, TKI treatment causes an undesired 
increase in endogenous miR-126 levels, thereby enhancing LSC quiescence and persistence. 
Genetic miR-126 KO in LSC and/or EC, or treatment with a novel CpG-miR-126 inhibitor 
targeting miR-126 in both LSC and EC enhances the in vivo anti-leukemic activity of TKI and 
significantly diminishes LSC leukemia-initiating capacity, thereby providing a novel and effective 
strategy to eliminate LSC in CML.    
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Introduction 
Chronic myelogenous leukemia (CML) is a clonal myeloproliferative disorder characterized at 
the cytogenetic level by the translocation of chromosomes 9q34 and 22q111, which creates a 
fusion gene, BCR-ABL that encodes a constitutively activated tyrosine kinase responsible for 
transforming normal hematopoietic stem cells (HSC) into leukemia stem cells (LSC). This 
ultimately leads to growth factor-independent proliferation and enhanced survival of clonal HSC 
and hematopoietic progenitor cells (HPC), resulting in a clinically uncontrolled myeloproliferation 
that eventually evolves into fatal blast crisis if left untreated. CML long-term (LT) HSC (or LSC) 
are at the apex of malignant clonal hematopoiesis and initiate and maintain leukemia growth. In 
CML, LSC activity is restricted to the LTHSC-enriched Lin-CD34+CD38-CD90+ population for 
humans, and the Lin-Sca-1+c-Kit+Flt3-CD150+CD48- population for mice2. CML LSC are thought 
to reside in a leukemia niche that may be anatomically and functionally different from that of 
normal HSC.  
Currently, oral tyrosine kinase inhibitors (TKI) are used as the first-line treatment to induce long-
term disease remission in CML patients. Although most patients treated with TKI monotherapy 
achieve major clinical and molecular responses, cells from the original BCR-ABL clone 
frequently persist, likely due to the failure of these agents to eliminate CML LSC3, and treatment 
discontinuation frequently results in disease relapse. Thus, identification of mechanisms that 
support CML LSC homeostasis is clinically relevant as it may enable us to design novel 
targeting strategies aimed at a complete disease elimination and discontinuation of expensive 
life-long TKI therapy, without increased risk of disease progression. 
MicroRNAs (miRNAs) are short non-coding RNAs that regulate translation of target messenger 
RNAs (mRNAs) into proteins that are involved in homeostatic mechanisms of normal cells4. 
Deregulation of endogenous miRNA production and abnormal extracellular trafficking have been 
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reported in both solid tumors and hematologic malignancies, including acute and chronic 
leukemia, and have been shown to play relevant roles in initiation and maintenance of malignant 
cellular clones5. In particular, miR-126-3p (miR-126) highly expressed in normal HSC and HPC 
restrain these cells from engaging into cell-cycle progression during hematopoiesis6. Our group 
and others have also shown that increased miR-126 expression enhances the frequency of 
quiescent LSC and is associated with a worse outcome in acute myeloid leukemia (AML)7-10. 
More recently, stable up-regulation of miR-126 in a mouse model led to development of acute 
lymphoblastic leukemia11. Thus, these results establish a key role for miR-126 in normal and 
clonal hematopoiesis. 
It is also known that miR-126 is specifically and highly expressed in endothelial cells (EC) and 
regulates angiogenesis12. Anatomical and functional connections between the endothelium and 
normal HSC that regulates normal hematopoiesis have recently been reported13. Herein we 
hypothesized that miR-126 may also mediate a similar functional interplay between EC and LSC 
in the leukemia BM niche and in turn regulate CML growth. Consistent with this hypothesis, we 
showed that EC supply miR-126 to CML LSC to modulate quiescence and self-renewal clonal 
activities. In fact endogenous miR-126 in CML LSC was shown to be down-regulated through 
SPRED1 which was phosphorylated by BCR-ABL and interfered with Exportin-5 (Exp-5)-
mediated miR-126 biogenesis. Thus, to achieve levels of mature miR-126 sufficient to sustain 
quiescence and preserve clonal hematopoiesis, CML LSC relied on exogenously supplied miR-
126 from EC. We demonstrated the biological relevance of miR-126 trafficking from EC to CML 
LSC in the leukemia niche using genetic miR-126 knock-out (KO) mouse models. Notably, as 
BCR-ABL down-regulated miR-126, inhibition of BCR-ABL by TKI led to an undesired increase 
in endogenous miR-126 levels and in turn in the frequency of quiescent CML LSC with 
repopulating capacity. Consistent with these results, we showed that the combination of TKI 
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with a novel miR-126 inhibitor targeting miR-126 in both EC and CML LSC cells led to the 
elimination of CML LSC.  
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Results 
Higher miR-126 levels are associated with human and mouse CML LSC 
Immunophenotypically defined subsets of HPC [Lin-CD34+(CD34+) and Lin-CD34+CD38+ 
(CD38+)], HSC [Lin-CD34+CD38- (CD38-) and Lin-CD34+CD38-CD90- (CD90-)] and LTHSC [Lin-
CD34+CD38-CD90+ (CD90+)] were sorted from normal donors’ (n=12) and newly diagnosed 
chronic phase (CP) CML patients’ (n=12) peripheral blood (PB) and BM samples. miR-126 
expression was measured using quantitative RT-PCR (QPCR). LTHSC in both normal and CML 
samples showed the highest expression of miR-126 (Fig. 1a, b).  
 
Similar results were obtained in wild-type (WT) B6 and inducible SCLtTA/BCR-ABL transgenic 
B6 mice, a well established CML mouse model14.  Lin-Sca-1-c-Kit- (L-S-K-), Lin-Sca-1-c-Kit+ (L-S-
K+) [including common myeloid progenitors (CMP), granulocyte-macrophage progenitors (GMP) 
and megakaryocyte-erythrocyte progenitors (MEP)], Lin-Sca-1+c-Kit+ (LSK) and LTHSC (LSK 
Flt3-CD150+CD48-) cells were isolated from the BM of WT mice and CML mice after BCR-ABL 
induction by tetracycline withdrawal (Supplementary Fig. 1a). As in human samples, normal and 
CML LTHSC showed the highest expression of miR-126 (Fig. 1c, d).  
 
The association of miR-126 with quiescence in CML LSC was proven by transducing human 
CML Lin-CD34+CD38- cells (HSC) and mouse CML LTHSC with GFP-expressing miRZip anti-
miR-126 (miR-126 KD) or miR-126 precursor (overexpression, OE) lentiviral vectors. GFP+ cells 
were selected and cultured for 72 hours (h) in StemSpan™ Serum-Free Expansion Medium II 
(SFEM II) supplemented with low concentrations of growth factors (GF)15. Results for human 
HSC are shown in Fig. 1e-i and for mouse LTHSC in Fig.1j-m. miR-126 KD increased cell 
cycling and apoptosis, decreased colony forming cells (CFC) and CFC replating efficiency. 
7 
 
Conversely, miR-126 OE decreased cell cycling and apoptosis, and increased CFC replating 
efficiency. We validated these results in vivo, first showing that quiescent Hoechst-Pyronin- (G0) 
fraction of CML LTHSC from the induced SCLtTA/BCR-ABL mouse (CD45.2) expressed 
significantly higher miR-126 levels than the proliferating Hoechst+/-Pyronin+ (G1/G2/S/M) fraction 
of CML LTHSC (p= 0.0019; Fig. 1n), and then demonstrating that the quiescent CML LTHSC 
had a significantly higher rate of long-term engraftment and leukemogenic capacity than the 
proliferating CML LTHSC after transplant into CD45.1 congenic recipient mice (Fig. 1o-p). 
 
BCR-ABL down-regulates miR-126 expression in CML cells 
While miR-126 has similar patterns of expression and function in CML as in normal 
hematopoiesis6, we noted that miR-126 levels were consistently lower in CML subpopulations 
compared to their normal counterparts, in both human and mouse. In human samples, CML Lin-
CD34+CD38- (HSC) and Lin-CD34+CD38-CD90+ cells (LTHSC) had significantly lower miR-126 
levels than their normal counterparts (Fig. 2a-b), and significant differences were also observed 
in the mouse (Fig. 2c). Consistent with this finding, CML HSC and LTHSC expressed higher 
levels of PIK3R2 and SPRED1, two validated targets known to be suppressed by miR-
1266,9,12,16,17, than their normal counterparts (Supplementary Fig.1b, c).  
The differential expression of miR-126 observed between normal and CML cells led us to 
postulate that BCR-ABL itself was involved in lowering endogenous miR-126 levels in CML 
cells. To test this hypothesis, normal mouse BM LSK cells were transduced with a BCR-ABL 
retroviral or control vector and GFP+ cells were selected and cultured for 3 days. Upon BCR-
ABL induction (Fig. 2d), miR-126 expression decreased (Fig. 2e) and PIK3R2 and SPRED1 
increased compared to the control cells (Supplementary Fig. 1d, e) along with a concurrent 
increase in cell cycling (Fig. 2f) and cell growth (Fig. 2g) rates. To further validate this finding, 
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LTHSC from non-induced BCR-ABL transgenic mice were sorted and cultured with or without 
tetracycline (2µg/ml). Upon tetracycline withdrawal and BCR-ABL induction (Fig. 2h), we 
observed reduced miR-126 levels (Fig. 2i) and increased cell cycling (Fig. 2j) and cell growth 
(Fig. 2k) rates compared with non-induced controls. Conversely, BCR-ABL inhibition using 2 or 
5 µM nilotinib (NIL), a first-line TKI for CML treatment, led to increased miR-126 expression (Fig. 
2l-n), decreased PIK3R2 and SPRED1 levels (Supplementary Fig. 1f, g) and an increased 
fraction of quiescent cells in the human CML HSC population (Fig. 2o), but not in normal 
counterpart (Supplementary Fig. 1h), compared with vehicle alone. BCR-ABL inhibition with NIL 
also resulted in increased miR-126 expression in human BCR-ABL+ K562 cells (Supplementary 
Fig. 1i).  
BCR-ABL deregulates miR-126 biogenesis 
While CML cells harbored lower levels of mature miR-126 than normal cells, we noted that 
BCR-ABL-positive cells had higher levels of primary (pri-) and precursor (pre-) miR-126 (Fig. 3a, 
b). This led us to hypothesize that BCR-ABL could interfere with miR-126 biogenesis.  
RAN (RAS-related nuclear protein) is a GTP-binding nuclear protein and a member of the RAS 
super family. It forms a protein complex with Exp-5 and RCC1, which are involved in miRNA 
nucleus-to-cytoplasm shuttling and maturation18. SPRED1 requires activation via tyrosine 
phosphorylation to act as a negative regulator of the members of the RAS superfamily19. We 
therefore postulated that the BCR-ABL tyrosine kinase may phosphorylate SPRED1, allowing 
SPRED1 to bind with RAN and in turn interfere with RAN/Exp-5/RCC1-mediated shuttling and 
maturation of miR-126 in CML cells. Using immunofluorescence (IF), immunoprecipitation (IP) 
and in vitro kinase activity assays of BCR-ABL+ primary CD34+ and/or K562 cells, we showed 
that SPRED1 co-localized with BCR-ABL to the cytoplasm (Fig. 3c), was directly 
phosphorylated by BCR-ABL (Fig. 3d), and formed an intra/perinuclear protein complex with 
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RAN whose binding with Exp-5/RCC1 complex decreased (Fig. 3e, f). NIL treatment reversed 
these effects, resulting in SPRED1 de-phosphorylation (Fig.3d, left panel), decreased 
interaction and co-localization of SPRED1 with RAN (Fig. 3f), increased RAN/Exp-5/RCC1 
complex (Fig. 3g-h), decreased pri- and pre-miR-126 levels, and increased mature miR-126 
levels (Fig. 3i).  Cell washing to remove NIL restored the binding of SPRED1 with RAN, 
decreased the binding of RAN with Exp-5/RCC1 (Fig. 3j), increased levels of pri-miR-126 (Fig. 
3k) and reduced levels of mature miR-126 (Fig. 3k, l). Northern blotting confirmed that the ratio 
of pri- and pre-miR-126 to mature miR-126 decreased upon exposure of BCR-ABL+ cells to NIL 
and increased upon NIL washing-off (Fig. 3m). SPRED1 knock-down (KD) by siRNA in BCR-
ABL+ primary CD34+ and K562 cells consistently enhanced formation of the RAN/Exp-5/RCC1 
complex (Fig. 3n) and resulted in decreased pri- and pre-miR-126 (Fig. 3o) and increased 
mature miR-126 (Fig. 3o, p). Finally, RAN KD by siRNA resulted in increased pri- and pre-miR-
126 and reduced mature miR-126 levels (Fig. 3q-r). 
 
We conclude that in CML cells, miR-126 levels are reduced through BCR-ABL-induced 
SPRED1 phosphorylation that interferes with RAN/Exp-5/RCC1-mediated miR-126 biogenesis.  
Given that miR-126 suppresses SPRED1, reduced levels of mature miR-126 are likely to cause 
a further increase in SPRED1, thereby amplifying an autoregulatory microcircuit, through which 
endogenous levels of miR-126 are controlled by its own target (SPRED1) and are progressively 
reduced in BCR-ABL+ cells via a feedback loop.   
 
Endothelial cells in the niche supply miR-126 to CML LTHSC 
Given that miR-126 is necessary for quiescence of LTHSC, and BCR-ABL activation causes 
down-regulation of mature miR-126 and cell cycle engagement, we then reasoned that BCR-
ABL+ LTHSC may be supported by an exogenous source of miR-126 to maintain quiescence 
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and cell cycle control and ultimately prevent clonal exhaustion. BCR-ABL+ LTHSC mainly reside 
in the BM niche with multiple regulatory non-hematopoietic cell types. Previous studies have 
shown that miR-126 is one of the most abundantly expressed miRNAs in EC and is involved in 
angiogenesis20,21. Consistent with this, we found that BM EC (CD45-Ter119-CD31+) expressed 
the highest levels of miR-126 compared with LTHSC and other BM microenvironmental stromal 
cell populations, including osteoblasts (OB; CD45-Ter119-CD31-CD166+Sca-1-)22 and 
mesenchymal stem cells (MSC; CD45-Ter119-CD31-CD166-Sca-1+)23 in both normal and CML 
mice (Fig. 4a, b).  
Thus we hypothesized that EC could supply miR-126 to CML LTHSC. To prove this hypothesis, 
EC from the femur calcified bone and marrow of SCLtTA/BCR-ABL mice were sorted and 
transduced with a GFP-expressing miR-126 KD lentiviral or control vector (Fig. 4c). LTHSC from 
induced SCLtTA/BCR-ABL mice were co-cultured with GFP+ control or miR-126 KD EC or 
cultured alone (i.e., no EC) for 96h and analyzed for cell cycle and expansion. After we collected 
LTHSC in culture suspension, we also separately collected the EC-attached LTHSC by flushing 
them gently with PBS buffer. Complete cell detachment was confirmed by microscopy and 
staining for CD45 to exclude EC contamination. CML cells co-cultured with control EC showed 
higher miR-126 levels (Fig. 4c), decreased cell cycling (Fig. 4d), decreased apoptosis (Fig. 4e), 
decreased cell growth (Fig. 4f), and increased frequency of LTHSC (Flt3-CD150+CD48- LSK) 
(Fig. 4g), compared to the cells co-cultured with miR-126 KD EC or cultured alone. The highest 
miR-126 levels were found in the LTHSC attached to control EC (Fig. 4h). CML LTHSC 
(CD45.2, 1000 cells/mouse) co-cultured with control or miR-126 KD EC, or cultured alone, for 
96h were then transplanted into congenic CD45.1 recipient mice. CML LTHSC co-cultured with 
control EC generated higher white blood cell (WBC) counts, higher CML engraftment levels and 
reduced survival (p=0.04) in recipient mice, compared with CML LTHSC co-cultured with miR-
126 KD EC or cultured alone (Fig. 4i-k).  
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A recent report showed that in normal BM, Sca-1+ EC from arterial blood vessels are associated 
with quiescent HSC, whereas Sca-1− EC from permeable sinusoidal blood vessels are 
associated with proliferative HSC13. We then hypothesized that a similar association between 
EC immunophenotypic subpopulations and adjacent LTHSC cell-cycle status may exist in CML 
mice and, given the role of miR-126 in cell quiescence, correlate with miR-126 levels. In fact, 
upon sorting EC and LTHSC from endosteal marrow (endosteal) and central marrow (central) of 
CML (and normal) mice, we found that ˃70% of endosteal EC were Sca-1+ and ˃80% of central 
EC were Sca-1-, Sca-1+ EC expressed higher miR-126 levels than Sca-1- EC, therefore, overall 
endosteal EC had higher miR-126 levels than central EC (Fig. 4l-o). Accordingly, endosteal 
LTHSC showed higher levels of miR-126 (Fig. 4p) and were more quiescent compared to 
central LTHSC (Fig. 4q-s). These results demonstrate a direct association between miR-126 
levels in EC and cell cycle status of adjacent LTHSC, and support an active trafficking of miR-
126 from EC to LTHSC in vivo.  
 
To verify the support role of EC-supplied miR-126 for leukemia growth, we generated CML or 
normal mice with miR-126 conditional knock-out (c-KO) in LTHSC/LSC or EC or both. We 
crossed miR-126(c-KO) mice (gift of Dr. Calvin Kuo) with Mx1-cre+, Tie2-cre+ and 
SCLtTA/BCR-ABL transgenic mice to obtain conditional miR-126 KO in the following strains: 
miR-126(c-KO)/Mx1-cre, SCLtTA/BCR-ABL/miR-126(c-KO)/Mx1-cre, miR-126(c-
KO)heterozygous(het)/Tie2-cre  and miR-126(c-KO)homozygous(hom)/Tie2-cre. After injecting 
miR-126(c-KO)/Mx1-cre+ (Mx1+) mice with polyinosine-polycytosine (pIpC) to obtain miR-126 
KO in normal HSC, we observed no significant changes in WBC counts in PB (not shown) or 
BM mononuclear cell subpopulations (including LTHSC) compared to control (Mx1-) mice after 
16 weeks of follow-up (Fig. 5a-b). Targeted miR-126 KO in CML LSC was then obtained with 
tetracycline withdrawal to induce BCR-ABL expression and pIpC injection to induce “cre” 
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activation in SCLtTA/BCR-ABL/miR-126(c-KO)/Mx1+ mice. Reduction of miR-126 levels by 60% 
(Fig. 5c) resulted in a significantly delayed CML development (p=0.047) and increased survival 
(p=0.04) in SCLtTA/BCR-ABL/miR-126(c-KO)/Mx1+ mice compared with SCLtTA/BCR-
ABL/miR-126(c-KO)/Mx1- controls (Fig. 5d-e). 
 
To confirm that these results were not attributable to “leaky” miR-126 down-regulation in the 
non-hematopoietic compartment, CD45.2 CML LTHSC from BCR-ABL-induced and pIpC-
injected SCLtTA/BCR-ABL/miR-126(c-KO)/Mx1+ or Mx1- mice were sorted and transplanted 
into CD45.1 congenic recipient mice (Fig. 5f). Recipients transplanted with Mx1+ (miR-126 KO) 
CML LTHSC (Fig. 5g) showed a similar trend for decreased CML development and increased 
survival compared with recipient mice transplanted with Mx1- control CML LTHSC (Fig. 5h-j).  
 
To assess the contribution of EC-derived miR-126 to leukemia growth, we then sorted LTHSC 
from BCR-ABL-induced CD45.1/CD45.2 SCLtTA/BCR-ABL mice (generated by crossing 
CD45.2 SCLtTA/BCR-ABL B6 mice with CD45.1 B6 mice to track donor cells) and transplanted 
them into CD45.2 congenic miR-126(c-KO)/Tie2-cre- (Tie2-) (WT miR-126 in EC), miR-126(c-
KO)het/Tie2-cre+(Tie2+) (heterozygous miR-126 KO in EC), or miR-126(c-KO)hom/Tie2+ 
(homozygous miR-126 KO in EC) recipient mice (Fig. 5k). Both het and hom Tie2+ recipient 
mice showed reduced CML cell engraftment, delayed CML development and significantly 
increased survival compared with Tie2- recipients at 16 weeks after transplant (Fig. 5l-o; 
p=0.009 and 0.0003 for survival of het Tie2+ and hom Tie2+ mice respectively), with a miR-126 
dosage effect (70% of hom Tie2+ mice versus 10% of het Tie2+ mice were alive at 28 weeks; 
Fig. 5o). Of note, CD45.1 normal LTHSC did not generate a significant difference in donor cell 
output in PB and BM from CD45.2 miR-126(c-KO)het/Tie2+ recipients compared with miR-
126(c-KO)het/Tie2- recipients after 16 weeks of follow-up (not shown).  
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Next, CML LTHSC from BCR-ABL-induced and pIpC-injected SCLtTA/BCR-ABL/miR-126(c-
KO)/Mx1+ or Mx1- mice were transplanted into miR-126(c-KO)het/Tie2+ or Tie2- recipient mice, 
respectively (Fig. 5p) to assess the functional impact of a concurrent miR-126 KO in both 
LTHSC and EC. Tie2+ mice transplanted with Mx1+ CML LTHSC showed a significantly 
delayed CML development (p=0.007) and prolonged survival (p=0.002) compared with Tie2- 
mice transplanted with Mx1- CML LTHSC (Fig. 5q-r).  At day 200, 83% of the mice with miR-126 
KO in both EC and LTHSC, but none of the controls with normal miR-126 in both EC and 
LTHSC, were alive.    
 
These results support a relevant role of the EC-derived miR-126 in sustaining leukemia growth 
in the CML LSC niche, and provide insights into a novel microenvironment-driven miRNA 
regulatory mechanism of CML leukemogenesis.  
 
To validate these results in humans, we first showed that human umbilical vein EC (HUVEC) 
expressed significantly higher levels of miR-126 compared with human CML CD34+ 
subpopulations (Supplementary Fig. 2a). We performed miR-126 KD in HUVEC using lentiviral 
or control (ctrl) vector transduction (Supplementary Fig. 2b, c), and co-cultured CML Lin-
CD34+CD38- cells (HSC) with miR-126 KD or ctrl HUVEC for 96h. CML HSC co-cultured with 
ctrl HUVEC had significantly higher miR-126 expression (Supplementary Fig. 2d, e) and 
decreased cell cycle entry and apoptosis (Supplementary Fig. 2f-h) compared with CML cells 
co-cultured with KD HUVEC or cultured alone. We detected an increased proportion of CD34+ 
cells among CML cells co-cultured with ctrl HUVEC compared with CML cells co-cultured with 
KD HUVEC or cultured alone for 96h (Supplementary Fig. 2i). CML CD34+ cells co-cultured 
alone or with ctrl or miR-126 KD HUVEC for 96h were then transplanted into irradiated (300cGy) 
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NSG-SGM3 (NOD-scid gamma IL3, GM-CSF, SCF triple transgenic) mice. BCR-ABL 
expression in BM cells collected at 16 weeks after transplantation confirmed CML cell 
engraftment in recipient mice (Supplementary Fig. 2j). We observed a significant increase in 
human CD45+ cell engraftment in mice receiving cells co-cultured with ctrl HUVEC compared 
with the mice receiving cells co-cultured with KD HUVEC or cultured alone (Supplementary Fig. 
2k-l).  
To determine the mechanisms of intercellular miR-126 trafficking between EC and HSC, we first 
isolated EVs from ctrl and miR-126 KD HUVEC by differential ultracentrifugation method. Using 
electron microscopy and nanoparticle tracking analysis by NanoSight, we determined that the 
size range of the EVs isolated from the supernatants of both control and miR-126 KD HUVEC 
was 40-150 nm (peaks at 105 and 125 nm, respectively, Supplementary Fig. 3a-b). By western 
blot, we showed expression of exosome-specific proteins (i.e., CD63, TSG101) and EV-
associated protein (i.e., HSP90)24,25 and lack of the non EV-associated protein (i.e., the 
mitochondrial protein Cytochrome C) in EVs recovered from HUVEC (Supplementary Fig. 3c). 
Next, we isolated a fraction from HUVEC-derived EVs using magnetic beads coated with anti-
CD63 antibody. We confirmed expression of exosome-specific proteins on this EV fraction using 
antibodies to tetraspanins (i.e., CD63, CD9 and CD81) by Cytofluorimetric analysis 
(Supplementary Fig. 3d). Significantly higher miR-126 levels were found in CD63+ EV fraction 
compared with CD63- EV fraction by QPCR (0.77 versus 0.19, Supplementary Fig. 3e). These 
results suggest that EVs from HUVEC contain miR-126. Notably the highest miR-126 levels 
were detected in the EVs obtained from ctrl HUVEC compared to those obtained from miR-126 
KD HUVEC or from human normal and CML Lin-CD34+CD38- HSC cells (Supplementary Fig. 
3f). 
 
15 
 
To demonstrate the intercellular trafficking of miR-126, we labeled miR-126 with a fluorescence 
probe in cultured HUVEC cells (Supplementary Fig. 3g), subjected the supernatant from these 
cells to differential ultracentrifugation and added the collected EVs to BCR-ABL+ K562 cells in 
culture. A miR-126 fluorescence signal was then detected in the K562 cells by confocal 
microscopy (Supplementary Fig. 3h). To corroborate these results, human CML HSC were 
cultured for 96h with EVs (5x109 particles/ml measured by NanoSight, equivalent to 5µg/ml 
measured by standard protein quantification method) isolated from ctrl or KD HUVEC or 
cultured alone. CML HSC co-cultured with ctrl HUVEC-derived EVs had significantly increased 
miR-126 levels (Supplementary Fig. 3i) and reduced cell cycling and apoptosis rates 
(Supplementary Fig. 3j-m) compared with the cells co-cultured with KD HUVEC-derived EVs or 
cultured alone. Furthermore, miR-126 KO CML LTHSC from BCR-ABL-induced and pIpC-
injected SCLtTA/BCR-ABL/miR-126(c-KO)/Mx1-cre+ mice were co-cultured with ctrl or miR-126 
KD HUVEC-derived EVs or cultured alone for 48 hours.  MiR-126 KO CML cells co-cultured with 
ctrl HUVEC-derived EVs showed significantly increased miR-126 levels (Supplementary Fig. 3n) 
and reduced cell cycling and apoptosis rates (not shown) compared with the cells co-cultured 
with KD HUVEC-derived EVs or cultured alone.  
 
Primary CML CD34+ cells co-cultured with EVs (5x109 particles/ml) from ctrl or miR-126 KD 
HUVEC for 96h were then transplanted into NSG-SGM3 mice. The mice receiving cells co-
cultured with ctrl HUVEC-derived EVs showed enhanced human CD45+ (p=0.001; 
Supplementary Fig.3o) and CD45+CD34+ (p=0.0008; Supplementary Fig.3p) BM engraftment at 
16 weeks, compared with mice receiving cells co-cultured with KD HUVEC-derived EVs. QPCR 
confirmed that the engrafted cells in both groups were BCR-ABL+ (not shown). We also sorted 
CML LTHSC from induced CD45.2 SCLtTA/BCR-ABL mice and co-cultured them with ctrl or KD 
HUVEC-derived EVs for 96h and then transplanted into CD45.1 recipient mice. LTHSC co-
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cultured with ctrl HUVEC-derived EVs showed increased miR-126 expression (p=0.009; 
Supplementary Fig.3q), enhanced CML progression (p=0.002), increased engraftment rate 
(p=0.06), and reduced survival (p=0.04) in recipient mice compared with LTHSC co-cultured 
with KD HUVEC-derived EVs (Supplementary Fig.3r-t). Altogether, these observations suggest 
that EVs-mediated trafficking carries miR-126 from EC to LTHSC.  
 
miR-126 knockdown enhances TKI-mediated targeting of CML LSC 
  
Given that BCR-ABL activity reduces endogenous levels of miR-126 in LTHSC and that 
pharmacologic inhibition of BCR-ABL by NIL increases miR-126 levels and the frequency of 
quiescent LTHSC (Fig. 2d-o), we then postulated that miR-126 down-regulation may enhance 
the anti-leukemic activity of TKI and eliminate CML LSC. To test this hypothesis, we subjected 
human CML HSC to miR-126 KD or OE by GFP-expressing lentiviral transduction. GFP+ cells 
were selected and cultured for 4 days in SFEM II supplemented with low concentrations of GF15, 
in the presence of NIL (Fig. 6a). We showed increased cell cycling and apoptosis (Fig. 6b-c) 
and decreased cell growth, CFC and CFC replating efficiency in the miR-126 KD and NIL-
treated cells compared with NIL-treated control cells (Fig. 6d-f). Conversely, we demonstrated 
decreased cell cycling and apoptosis (Fig. 6b-c) and increased CFC and CFC replating 
efficiency in miR-126 OE and NIL-treated cells (Fig. 6e, f) compared with NIL-treated control 
cells. Similar results were obtained in CML LTHSC from SCLtTA/BCR-ABL mice (Fig. 6g-k).  
 
To prove that miR-126 KD could enhance the anti-leukemic activity of TKI, human CML HSC 
were transduced with miR-126 KD lentiviral or control vector; selected GFP+ cells were treated 
with NIL (5µM) for 4 days and then transplanted into irradiated NSG-SGM3 mice. We observed 
reduced engraftment of human CD45+ cells in PB at 4 weeks (Fig. 6l) and in BM at 16 weeks 
(Fig. 6m and Supplementary Fig. 4a) in the recipient mice receiving miR-126 KD cells treated 
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with NIL compared to controls. QPCR analysis showed that BCR-ABL levels were reduced in 
BM cells from NSG-SGM3 mice receiving miR-126 KD CML cells (Supplementary Fig. 4b).  
 
To test if miR-126 down-regulation in EC also enhanced the CML HSC sensitivity to TKI, we 
cultured human CML HSC alone or with HUVEC ± miR-126 KD, with or without NIL for 72h. We 
observed significantly increased apoptosis and decreased cell growth and CFC in CML HSC co-
cultured with KD HUVEC compared with CML HSC cultured with ctrl HUVEC, with or without 
NIL (Supplementary Fig. 4c-e). Of note, CML HSC co-cultured with KD HUVEC-derived EVs 
also showed significantly increased apoptosis and decreased cell growth compared to CML 
HSC co-cultured with ctrl HUVEC-derived EVs, with or without NIL (Supplementary Fig. 4f, g). 
Next, CML LTHSC from induced CD45.1/CD45.2 SCLtTA/BCR-ABL mice were sorted and 
transplanted into CD45.2 miR-126(c-KO)het/Tie2+ or Tie2- mice. Once we confirmed CML 
development, we treated the mice with NIL (50mg/kg, daily by oral gavage) or vehicle for 3 
weeks. Vehicle-treated Tie2+ mice showed a delayed CML development (p=0.02) and 
increased survival (p=0.001) compared with vehicle-treated Tie2- mice. NIL-treated Tie2+ mice 
showed significantly reduced WBC counts in PB (p=0.03) and increased survival (p=0.02) 
compared with NIL-treated Tie2- mice (Fig. 6n-p). All NIL-treated Tie2+ mice were alive at day 
150. Altogether, these results support the hypothesis that miR-126 down-regulation in EC and 
CML HSC enhances the anti-leukemic activity of TKI. 
Although the mechanistic basis for how miR-126 KD enhanced TKI activity may be related to 
altered expression levels of multiple miR-126 targets involved in pathways of proliferation and 
survival, we observed that, consistent with previous reports26,27, NIL treatment in CML CD34+ 
cells enhanced MAPK/ERK signaling which has been shown to promote cell survival and inhibit 
apoptosis through BCL-2 up-regulation (Supplementary Fig. 4h). Thus, we reasoned that NIL-
induced up-regulation of miR-126 and in turn down-regulation of SPRED1 (Supplementary Fig. 
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4h, i), a reported inhibitor of the MAPK/ERK pathway, could contribute to this effect. In fact, 
miR-126 KD induced SPRED1 up-regulation and decrease of phospho-ERK (p-ERK) and BCL-2 
levels (Supplementary Fig. 4j-k). Consistently, SPRED1 KD by siRNA increased p-ERK and 
BCL-2 levels, and rescued NIL-induced apoptosis (Supplementary Fig. 4l-o) in CML CD34+ 
cells. NIL-induced apoptosis was enhanced by the MEK inhibitor PD0325901 or BCL-2 KD 
(Supplementary Fig. 4p-s). Thus, these results support a model in which NIL induces miR-126 
up-regulation, decreases SPRED1, results in spurious activation of the MAPK/ERK pathway, 
and ultimately increases BCL-2 levels; while miR-126 KD counteracts these effects, thereby 
increasing the anti-leukemic activity of NIL.   
 
Effective in vitro and in vivo uptake and gene silencing effects of the CpG-miR-126 
inhibitor 
Given that miR-126 KD enhanced the anti-leukemic activity of NIL, we reasoned that miR-126 is 
likely an effective therapeutic target to eliminate LSC. microRNAs are generally targeted with 
oligonucleotide therapeutics (ONTs). It remains challenging to achieve an efficient and cell-
selective delivery of ONTs in vivo. Thus, we designed a novel miR-126 inhibitor by linking an 
anti-miR-126 oligodeoxynucleotide (ODN) to a cytosine guanine dinucleotide (CpG) ODN, a 
ligand for the intracellular Toll-like Receptor 9 (TLR9). To allow for systemic administration, the 
CpG-miR-126 inhibitor was chemically modified to resist serum nucleases using 
phosphothioation and 2’OMe-modified nucleotides in the CpG ODN and anti-miR-126 moieties, 
respectively.  We then compared the specificity and efficiency of this novel CpG-miR-126 
inhibitor uptake with a nanoparticle (NP) delivery method previously reported by our group8. We 
incubated K562 cells with fluorescently-labeled CpG-miR-126 inhibitor-Cy3 (CpG), human CD45 
antibody (Ab)- or Transferrin (TF)-conjugated NPs containing miR-126 inhibitor-Cy3 (Ab-NP or 
TF-NP), or naked miR-126 inhibitor-Cy3 (control), in the absence of any reagent(s) routinely 
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used for nucleic acid transfection.  Flow cytometric analysis at 4h and 24h (Supplementary Fig. 
5a-b) showed that CpG-miR-126 inhibitor-Cy3 was efficiently taken up by 99% of the K562 cells 
at both 4h and 24h, compared with only a fraction of the cells incubated with Ab-NP (24% for 4h 
and 30% for 24h) or TF-NP (74% for 4h and 88% for 24h).  K562 cells did not take up naked 
miR-126 inhibitor (control) (Supplementary Fig. 5b). Efficient miR-126 down-regulation by CpG-
miR-126 inhibitor-Cy3 in K562 cells was confirmed by QPCR at 24h (Supplementary Fig. 5c). 
We further showed by flow cytometry that, even without routinely used transfection reagents for 
nucleic acids, the CpG-miR-126 inhibitor-Cy3 was internalized by HUVEC as well as human 
normal and CML Lin-CD34+CD38- cells at 4h (Supplementary Fig. 5d-f); >95% cells were 
positive for CpG-miR-126 inhibitor-Cy3 uptake in all three cell types. The efficient miR-126 
down-regulation in HUVEC and HSC was also confirmed by QPCR (Supplementary Fig. 5g-i). 
We also observed increased cell cycling in both CpG-miR-126 inhibitor-treated normal and CML 
HSC compared to CpG-scrambled RNA (scrRNA)-treated controls (Supplementary Fig. 5j-k). 
Next, we evaluated CpG-miR-126 inhibitor-Cy3 uptake in murine CML BM, LTHSC and EC cells 
in vitro and in vivo. Following in vitro exposure to CpG-miR-126 inhibitor-Cy3, efficient uptake at 
4h and miR-126 down-regulation at 24h were confirmed by flow cytometry and QPCR, 
respectively (Supplementary Fig. 5l-m). We also observed increased cell cycling in normal and 
CML BM LTHSC treated with the CpG-miR-126 inhibitor (Supplementary Fig. 5n). Normal and 
CML mice were treated with one dose (5mg/kg, iv injection) of CpG-miR-126 inhibitor-Cy3. At 
16h post-treatment, efficient in vivo uptake was demonstrated by flow cytometry, in both LTHSC 
(56±5%) and EC (62±3%) isolated from femurs (Supplementary Fig. 5o). After CpG-miR-126 
inhibitor treatment (5mg/kg/day, iv, daily) for 3 days, LTHSC and EC were sorted and significant 
miR-126 down-regulation was confirmed by QPCR (Supplementary Fig. 5p-q). 
 
CpG-miR-126 inhibitor enhances in vivo targeting of CML LSC in combination with TKI 
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Given that CpG-miR-126 inhibitor was efficiently taken up by both normal LTHSC and EC and 
effectively down-regulated miR-126 expression, we then tested the effect of the inhibitor in 
normal mice to ensure that the compound did not have hematologic toxicity. WT B6 mice were 
treated with CpG-scrRNA (scrRNA) or CpG-miR-126 inhibitor (inhibitor, 5mg/kg/day i.v.) for 3 
weeks and BM cells were collected, analyzed and transplanted into recipient mice (3x105 BM 
cells/mouse). Compared with scrRNA-treated control mice, inhibitor-treated mice showed 
increased numbers of red blood cells (RBC), but no significant difference in WBC or platelets 
(PLT) in PB (Supplementary Fig. 6a-c), or in mononuclear cells, LTHSC, or EC in the BM 
(Supplementary Fig. 6d-f). This finding was in line with the observation that miR-126 down-
regulation in normal HSC increases hematological output6. In the recipient mice receiving BM 
cells from donor mice treated with scrRNA or inhibitor, we observed no significant differences in 
donor cell engraftment in PB, BM or spleen (Supplementary Fig. 6g-h) or in donor LTHSC 
number in BM (Supplementary Fig. 6i) at 16 weeks after transplantation. These data 
demonstrate a lack of pre-clinical toxicity of the inhibitor for normal hematopoiesis. 
We then tested the effects of the inhibitor alone and in combination with NIL on human and 
murine CML LTHSC in vivo. First we transplanted human CD34+ cells from CP CML patients 
into NSG-SGM3 mice. At 6 weeks after transplantation, the mice were divided into 4 groups and 
treated with scrRNA (5mg/kg i.v. 4 times a week), inhibitor (5mg/kg, i.v. 4 times a week), 
scrRNA + NIL (50mg/kg, daily by oral gavage), or inhibitor + NIL for 3 weeks, followed by 
assessment of human cell engraftment in PB, BM and spleen. Significantly reduced human 
CD45+, CD45+CD34+CD38- HSC and CD45+CD34+CD38-CD90+ LTHSC engraftment was seen 
in the BM of inhibitor+NIL treated recipient mice compared with scrRNA, inhibitor alone or NIL 
alone treated mice (Fig. 7a-c, Supplementary Fig. 6j). Fluorescence in situ hybridization (FISH) 
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analysis and QPCR confirmed that the engrafted human CD45+ cells were BCR-ABL positive 
(Supplementary Fig. 6k).  
Next, BM cells from SCLtTA/BCR-ABL mice (CD45.2) were transplanted into congenic B6 mice 
(CD45.1). Following confirmation of CML development at 4 weeks after transplantation, mice 
were treated as above with scrRNA, inhibitor, scrRNA + NIL, or inhibitor + NIL for 3 weeks. As 
EC-derived miR-126 plays a key role in LSC maintenance, we sorted BM EC from treated mice 
and confirmed significant miR-126 KD in total EC, Sca-1+ EC and Sca-1- EC from inhibitor-
treated mice compared with scrRNA-treated mice (Supplementary Fig. 6l-m). Mice receiving the 
combination of inhibitor + NIL had a significant reduction in the percentage of CD45.2+ CML 
cells in PB, spleen and BM (Fig. 7d-f), and a significant reduction in the numbers of CML LSK 
and LTHSC in spleen and BM compared with all other control groups (Fig. 7g-j). A cohort of 
mice was followed for survival studies after 3 weeks of treatment. All of the mice treated with 
scrRNA alone died of leukemia within 60 days after discontinuing treatment, whereas 50% of 
the mice treated with inhibitor or NIL alone and 90% of the mice treated with the combination of 
inhibitor and NIL survived (p=0.0012; Fig. 7k).  
To quantify the frequency of leukemia-initiating cells (LIC) after treatment, BM cells from 
leukemic mice treated with scrRNA, inhibitor, scrRNA + NIL, or inhibitor + NIL for 3 weeks were 
transplanted in limiting dilution into secondary congenic CD45.1 recipient mice. Treatment with 
the combination of inhibitor and NIL resulted in a significantly higher levels of depletion of LIC 
based on leukemia development in secondary recipient mice after 16 weeks of follow-up, 
compared with treatments with scrRNA alone, inhibitor alone or scrRNA + NIL (Fig. 7l). None of 
the secondary recipients that received BM cells from the mice treated with combination of 
inhibitor and NIL developed leukemia.  
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These results indicate that the combination of CpG-miR-126 inhibitor and NIL remarkably 
enhances eradication of CML LSC capable of engraftment in secondary recipients compared 
with NIL alone. 
Discussion 
We report here that a gradient of miR-126 expression follows a hierarchical order of 
hematopoietic differentiation, both in human and murine CML hematopoiesis, with more 
primitive stem cells or progenitors expressing higher levels of miR-126. Quiescent CML LTHSC 
have higher levels of miR-126 and a higher leukemia engraftment capacity than proliferating 
CML LTHSC. This finding was in line with the observation reported in normal hematopoiesis6.  
 
Unexpectedly, however, we observed that CML LTHSC had miR-126 levels significantly lower 
than their normal counterparts. This finding was consistent with a lower frequency of long-term 
repopulating cells observed within CML LTHSC compared to normal LTHSC, as shown by serial 
dilution LTHSC transplantation2. Indeed, we demonstrated that BCR-ABL expression lowered 
the levels of mature miR-126 and increased the levels of pri- and pre-miR-126, whereas 
pharmacologic BCR-ABL inhibition by TKI increased the levels of mature miR-126 and 
decreased the levels of pri- and pre-miR-126. Altogether, these data support a role of BCR-ABL 
in altering the biogenesis of endogenous miR-126. Of note, BCR-ABL-dependent deregulation 
of microRNAs is however unlikely to be restricted to down-regulation of miR-126. In fact, 
comparing LSK cells from non-induced versus induced CML mice, we found 33 miRNAs 
(including miR-126-3p and miR-126-5p, miR-125a-5p, 125b-5p, 181a-3p, 181b-5p, and 29b-3p) 
significantly decreased, and 75 miRNAs (including miR-142-3p and miR-142-5p, 146b-3p, 146b-
5p, and 486-5p) significantly increased (Supplementary Fig. 1j), suggesting distinct BCR-ABL-
dependent mechanisms of microRNA regulation.  
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To our knowledge, BCR-ABL-dependent down-regulation of miR-126 in CML cells and its 
mechanistic basis has not been previously reported. SPRED1, a validated miR-126 
target6,9,12,16,17, is a tyrosine kinase substrate known to inhibit GF-mediated activation of RAS 
protein family members and in turn the RAS/MAPK/ERK pathway18. Tyrosine residue 
phosphorylation is required for SPRED1 inhibition of RAS/MAPK/ERK activation19. We show 
here that SPRED1 is a substrate for BCR-ABL and that BCR-ABL/SPRED1 interplay is critical 
for miR-126 biogenesis. In fact, BCR-ABL-phosphorylated SPRED1 binds with RAN, a RAS 
family member, disrupts the RAN/Exp-5/RCC1 complex, which is involved in pre-miRNA 
nucleus-to-cytoplasm shuttling, and increases nuclear levels of pri- and pre-miR-126 and 
decreases cytoplasmic levels of mature miR-126. Conversely, BCR-ABL inhibition results in 
disruption of the binding of SPRED1 with RAN, and in turn enhances formation of the RAN/Exp-
5/RCC1 complex, increases levels of mature miR-126 and decreases levels of pri- and pre-miR-
126. Thus, we conclude that BCR-ABL mediates miR-126 down-regulation through SPRED1, 
which, once phosphorylated, inhibits the maturation of its miRNA regulator and in turn increases 
its own expression. This process likely creates an autoregulatory loop, where the higher the 
SPRED1 levels, the lower the mature miR-126 levels (Supplementary Fig. 1k).  
 
However, miR-126 is necessary for normal and clonal HSC quiescence, and a continuous 
down-regulation of miR-126 could cause clonal exhaustion6,10. Therefore, we reasoned that the 
endogenous, aberrantly BCR-ABL-activated SPRED1/miR-126 autoregulatory loop must be 
interrupted in order to maintain a reservoir of quiescent CML LSC. Previous reports suggest that 
BM EC participate in the regulation of normal hematopoiesis13,28. Here, we show that among the 
distinct BM leukemia niche cell populations, EC express the highest levels of miR-126 and 
supply miR-126 to CML cells, likely through EVs trafficking. Furthermore, consistent with the 
previous reports showing that Sca-1+ EC are associated with quiescent normal HSC and Sca-1- 
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EC associated with proliferating normal HSC in the marrow13, we show here that endosteal Sca-
1+ EC express higher levels of miR-126 and are associated with a larger quiescent fraction of 
BCR-ABL+ LTHSC, which also express higher miR-126 levels. In contrast, central Sca-1- EC 
express lower levels of miR-126 and are associated with a larger proliferating fraction of BCR-
ABL+ LTHSC, which also express lower miR-126 levels. Our data therefore support a functional 
interplay between EC and HSC in CML, resulting in a non-random BM distribution of the 
quiescent CML LSC fraction that are more likely to be found proximal to the higher miR-126-
expressing EC of the bone endosteum.  
 
To demonstrate the functional relevance of the LTHSC-EC miR-126 interplay to leukemia 
growth, we created a series of genetic murine models with miR-126 KO in either LTHSC 
(normal or BCR-ABL+) or EC or both. The decreased engraftment of CML LSC and improved 
survival observed in recipient mice with miR-126 KO in the endothelial compartment indicated 
that CML LTHSC and the BM microenvironment are functionally integrated through the miR-126 
LTHSC-EC intercellular trafficking. Of note, we could not completely exclude the possibility that 
decreased CML LTHSC quiescence and engraftment capacity resulted from EC functional 
changes induced by miR-126 KD, rather than from a simple decrease of miR-126 trafficking 
from EC to LTHSC. However, Kuo et al. previously showed that miR-126 KO mice had no 
significant changes of BM EC structure12. Moreover, we have not observed significant changes 
in the morphology, growth rate or growth patterns of miR-126 KD HUVEC or mouse EC 
compared with controls (not shown).  
 
Our results are clinically relevant to CML patients treated with TKI therapy. Persistence of CML 
LSC during TKI treatment is an active area of investigation, as these agents are remarkably 
potent against cycling cells, but fail to eliminate quiescent CML LSC3. Using primary CML cells 
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and CML murine models, we first showed that CML LSC resistance to TKI was likely mediated 
by SPRED1 de-phosphorylation caused by BCR-ABL inhibition that led to increased 
endogenous miR-126, which pushes LSC into a relatively treatment-refractory quiescent state. 
Furthermore, miR-126 up-regulation in TKI-treated CML CD34+ cells resulted in decreased 
SPRED1, a MAPK/ERK pathway inhibitor, which in turn resulted in a spurious activation of 
MAPK/ERK pathway and increased cell survival, likely mediated by BCL-226,27. These findings 
led us to hypothesize and prove, both in vitro and in vivo, that miR-126 KD in CML cells and/or 
EC enhances the anti-leukemic activity of TKI by counteracting the undesired miR-126 up-
regulation and SPRED1 down-regulation induced by TKI. In fact, we showed 100% survival of 
genetically engineered CML mice with miR-126 KD EC treated with TKI, thereby proving miR-
126 to be a suitable therapeutic target in CML.   
Thus to apply our work to clinical translation, we designed a novel CpG-miR-126 ODN inhibitor 
that could be efficiently taken-up by both hematopoietic and non-hematopoietic cells in the BM 
niche. We have previously shown that the uptake of CpG–ODN conjugated molecules depends 
on endocytosis by scavenger family dextran sulfate-sensitive receptors (SRs)29,30, which are 
expressed on the surface of normal and malignant myeloid cells31,32. Following SR-mediated 
internalization, CpG-conjugates bind to endosomal TLR9 and trigger their cytoplasmic release29. 
As a result, the TLR9-targeted delivery of ODNs overcomes endosomal retention, which has 
been identified to be the major issue hindering many delivery strategies (e.g. antibody-mediated 
delivery). SRs and TLR9 are both expressed on hematopoietic cells and EC33-36, and likely 
facilitate the efficient intracellular delivery of CpG-miR-126 inhibitor and its prompt release for 
pharmacologic activity. Our results indeed showed that the CpG-miR-126 inhibitor was taken up 
by both LTHSC and EC with ~80% efficiency in vitro and 40-70% in vivo (depending on the cell 
type) and led to a significant miR-126 down-regulation that translated into reduced LTHSC 
quiescence and frequency. The combination of CpG-miR-126 inhibitor and TKI significantly 
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increased survival, compared with either agent alone or vehicle. Furthermore, no leukemia 
development in secondary transplanted recipients was observed, thereby supporting our initial 
hypothesis that CML LSC elimination can be achieved by optimal therapeutic targeting of miR-
126. Importantly, we observed no hematologic toxicity in normal mice treated with CpG-miR-126 
inhibitor. Secondary transplantation of BM cells from normal mice treated with scrRNA or CpG-
miR-126 inhibitor did not show a significant difference in engraftment between the two groups. 
The enhanced in vivo effect of CpG-miR-126 inhibitor on TKI activity was also confirmed in a 
model of human CML CD34+ cells engrafted in immunodeficient mice.   
In summary, we report for the first time a complex interplay between BCR-
ABL/SPRED1/RAN/Exp-5/RCC1 in CML LSC, resulting in down-regulation of endogenous miR-
126 in CML LSC. CML LSC then rely on a microenvironment-driven trafficking of miR-126 from 
EC to LSC in the BM niche, to maintain a quiescent fraction of LSC with high leukemogenic 
capacity. Consistent with this model, we show that TKI treatment inhibits BCR-ABL-induced 
SPRED1 phosphorylation, which leads to an undesired increase of miR-126, down-regulation of 
SPRED1 and spurious activation of the MAPK/ERK pathway and increase of BCL-2. We proved 
that miR-126 KO enhances TKI activity in vivo and that this mechanism is therefore 
therapeutically targetable. Importantly, our novel CpG-miR-126 inhibitor, which is now being 
translated to the clinic, was active in both EC and LSC, and significantly enhanced the anti-
leukemic activity of TKI, thereby providing a proof-of-concept that this therapeutic approach is 
feasible for LSC elimination in CML patients (Supplementary Fig. 6n).  
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Experimental procedures 
Human samples 
Normal PB and BM samples were obtained from donors at City of Hope National Medical 
Center (COHNMC). CP CML samples were obtained from patients who have not received prior 
TKI treatment from COHNMC and Glasgow Experimental Cancer Medicine Centre and UK 
SPIRIT trials. All CML samples used in this study are P210 BCR-ABL positive confirmed by 
FISH analysis and QPCR. Mononuclear cells were isolated using Ficol separation. CD34+ cells 
were then isolated using a positive magnetic bead selection protocol (Miltenyi Biotech, 
Germany). All patients and healthy donors signed an informed consent form. Sample acquisition 
was approved by the Institutional Review Boards at the COHNMC and Greater Glasgow and 
Clyde NHS Trust, in accordance with an assurance filed with and approved by the Department 
of Health and Human Services, and met all requirements of the Declaration of Helsinki. 
Animal studies 
Inducible transgenic SCLtTA/BCR-ABL mice in the FVB/N background14 were backcrossed to 
the B6 background (CD45.2) for 10 generations. Transgenic BCR-ABL mice were maintained 
on tetracycline water at 0.5 g/L. Withdrawal of tetracycline results in expression of BCR-ABL 
and generation of a CML-like disease in these mice. Unless otherwise indicated, BCR-ABL 
expression was induced for 2-3 weeks by tetracycline withdrawal and then BM cells (both tibias 
and femurs) were collected for experiments. SCLtTA/BCR-ABL mice (CD45.2, B6) were also 
bred with CD45.1 B6 mice to produce CD45.1/CD45.2 SCLtTA/BCR-ABL mice as donors. miR-
126(c-KO) mice (B6, from Dr. Kuo, Stanford) were crossed with Mx1-cre, Tie2-cre (both from 
The Jackson Laboratory) and SCLtTA/BCR-ABL mice (all B6) to obtain the following strains: 
miR-126(c-KO)/Mx1-cre, miR-126(c-KO)/Mx1-cre/SCLtTA/BCR-ABL and miR-126(c-KO)/Tie2-
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cre. Recipient mice in the CD45.1 B6 background (Charles River) were used to allow tracking of 
donor CD45.2 cells after transplant. Recipient mice were 6 to 8 weeks old and were irradiated at 
900 cGy within 24h before transplantation. The number of mice for each study group was 
chosen based on the expected endpoint variation (i.e., engraftment rate and latency period of 
leukemia) and mice availability from distinct strains. The mice of the same gender and age were 
randomly divided into groups. Investigators were blinded to mice genotypes while performing 
treatment or monitoring engraftment or survival. Mouse care and experimental procedures were 
performed in accordance with federal guidelines and protocols approved by the Institutional 
Animal Care and Use Committee at the City of Hope.  
Engraftment of human cells in immunodeficient mice 
GFP+ cells (2×105 cells/mouse) selected from CML Lin-CD34+CD38- cells transduced with 
miRZip anti-miR-126 (126 KD) or control lentivirus (ctrl) were cultured with or without NIL (5µM) 
for 96h. Cells were then harvested, washed and transplanted via tail vein injection into 
sublethally irradiated (300cGy) 8 week old NOD.Cg-Prkdcscid Il2rg tm1Wjl Tg(CMV-
IL3,CSF2,KITLG)1Eav/MloySzJ mice ( NSG-SGM3, The Jackson Laboratory). 
Engraftment of human CD45+ cells in PB was monitored at 6 weeks. Mice were euthanized after 
16 weeks and marrow contents of femurs, spleen cells and blood cells were obtained at 
necropsy. To assess human cell engraftment, cells were labeled with anti-mouse CD45 and 
anti-human CD45 and CD33 antibody and analyzed by flow cytometry. To assess engraftment 
of malignant BCR-ABL expressing cells, BM cells obtained were evaluated for BCR-ABL mRNA 
levels by QPCR37.  
In vivo treatment of normal and transgenic BCR-ABL mice 
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BM cells (CD45.2) were obtained from SCLtTA/BCR-ABL mice at 4 weeks after induction of 
BCR-ABL expression by tetracycline withdrawal and transplanted by tail vein injection 
(106 cells/mouse) into recipient mice (CD45.1) irradiated at 900cGy. Blood samples were 
obtained 4 weeks after transplantation to confirm development of neutrophilic leukocytosis. Mice 
were treated with scrRNA (5mg/kg, 4 times a week by vein injection), CpG-miR-126 inhibitor 
(inhibitor, 5mg/kg, 4 times a week by vein injection), scrRNA + NIL (50mg/kg, daily by oral 
gavage), or inhibitor + NIL for 21 days. After 3 weeks of treatment, mice were euthanized and 
BM cells from right femur and spleen cells were analyzed for CML cell output. BM cells from the 
left femur of the treated mice were pooled and 4×106, 2×106, 1×106 and 5×105 cells/mouse (6 
mice/dose x 4 doses x 4 conditions=96  mice) were transplanted into recipient mice (CD45.1) 
irradiated at 900cGy. WBC counts and CML cell engraftment was monitored every 4 weeks. 
The mice were euthanized at 16 weeks, followed by assessment of donor CML cell engraftment 
in PB, BM and spleen. The fraction of mice showing evidence of CML development at 16 weeks 
after secondary transplantation was determined and the frequency of LIC was calculated using 
Poisson statistics. Another cohort of mice was followed for survival up to 60 days after 
discontinuation of treatment. To determine the in vivo effect of the CpG-miR-126 inhibitor on 
normal hematopoiesis, normal mice were treated with scrRNA or inhibitor for 3 weeks, followed 
by assessment of WBC, RBC, PLT in PB and BM subpopulations in BM.  
Statistics 
Results are expressed as mean ± SEM. Comparison between groups was performed by 
Student's t-test, Wilcox rank sum test, non-parametric Mann Whitney test or ANOVA, adjusting 
for multiple comparisons as appropriate. The log-rank test was used to assess significant 
differences between survival curves. All statistical analyses were performed using Prism version 
6.0 software (GraphPad Software). Sample sizes chosen are indicated in the individual figure 
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legends and were not based on formal power calculations to detect prespecified effect sizes. P 
values <0.05 were considered significant. Results shown represent mean ± SEM. ∗p < 0.05, ∗∗p 
< 0.01, ∗∗∗p < 0.001.  
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Figure 1: Human and mouse CML LSC express higher levels of miR-126 
(a,b) QPCR for miR-126 expression in HPC [Lin-CD34+(CD34+) and Lin-CD34+CD38+ (CD38+)], 
HSC [Lin-CD34+CD38- (CD38-) and Lin-CD34+CD38-CD90- (CD90-)] and LTHSC [Lin-
CD34+CD38-CD90+ (CD90+)] from (a) normal donors’ (n=12) and (b) newly diagnosed CP CML 
patients’ (n=12) blood and BM samples. (c-d) QPCR for miR-126 expression in BM 
subpopulations from normal and CML mice (n=6). CML Lin-CD34+CD38- cells were transduced 
with GFP-expressing miRZip anti-miR-126 (KD, MOI=20) or miR-126 precursor (OE, MOI=10) 
or control lentivirus (MOI=10-20). GFP+ cells were selected and cultured for 72h and then (e) 
miR-126 expression, (f) cell cycling, (g) apoptosis, (h) CFC and (i) CFC replating efficiency were 
measured (n=4). LTHSC from induced SCLtTA/BCR-ABL mice were transduced with miR-126 
KD, miR-126 OE, or control lentivirus (MOI=20). GFP+ cells were cultured for 72h and (j) miR-
126 expression, (k) cell cycling, (l) apoptosis, and (m) CFC were measured (n=4). Quiescent 
Hoechst-Pyronin- (G0) LTHSC and proliferating Hoechst+/-Pyronin+ (G1/G2/S/M) LTHSC 
(CD45.2 B6) were sorted and transplanted into recipient mice (CD45.1 B6, n=10). (n) QPCR for 
miR-126 expression in quiescent and proliferating LTHSC (n=3). (o) White blood cell (WBC) 
counts and (p) donor CML cell engraftment in PB of the recipient mice were measured (n=10). 
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Figure 2: BCR-ABL down-regulates miR-126 expression in CML cells 
(a-b) miR-126 expression in normal and CML cell populations from human samples (a) by 
QPCR (n=10) and (b) by miRNA staining and (c) from mouse BM by QPCR (n=6). Normal 
mouse BM LSK cells were sorted and transduced with a retroviral BCR-ABL or control construct. 
(d) BCR-ABL and (e) miR-126 expression (n=4) were measured by QPCR at 24h after 
transduction. (f) Cell cycling and (g) cell growth (n=3) at 48h after transduction are shown. 
LTHSC from non-induced BCR-ABL transgenic mice (tet off) were sorted and cultured in the 
presence or absence of tetracycline  (2µg/ml) to induce BCR-ABL. (h) BCR-ABL expression and 
(i) miR-126 levels (n=3) were measured by QPCR. (j) Cell cycling and (k) cell growth (n=3) were 
measured at 48h after BCR-ABL induction.  (l-n) miR-126 expression (n=3) in (l-m) human CML 
Lin-CD34+CD38- cells treated with and without NIL by QPCR and in (n) normal and CML Lin-
CD34+CD38- cells treated with and without NIL by miRNA staining and (o) cell cycling (n=4) of 
human CML Lin-CD34+CD38- cells treated with and without NIL.  
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Figure 3: BCR-ABL deregulates miR-126 biogenesis 
(a) pri-miR-126 (n=8) and (b) pre-miR-126 expression levels by QPCR (n=8) in human normal 
and CML cell populations. (c) BCR-ABL and SPRED1 co-staining in CML CD34+ cells by 
immunofluorescence (IF). K562 cells were treated with or without NIL for 24h and protein 
lysates were collected. (d) Immunoprecipitation (IP) with anti-SPRED1 and immunoblotting with 
anti-SPRED1 and anti-phosphotyrosine (p-Tyr) antibodies and in vitro kinase assay by IP with 
anti-c-Abl and immunoblotting with anti-SPRED1. (e) IP with anti-RAN and immunoblotting with 
anti-SPRED1 and anti-RAN antibodies were performed with K562 cells. (f) IF co-staining of 
SPRED1 and RAN in K562 cells treated with and without NIL. (g) SPRED1, RAN, RCC1 and 
Exp-5 expression in cytoplasmic (cyt) and nuclear (nu) fractions from K562 cells, treated with 
and without NIL, was measured by western blot. Densitometric quantification (normalized to 
internal control) is shown under the blots. (h) IP with anti-RAN and immunoblotting with anti-
SPRED1, RAN, Exp-5 and RCC1 antibodies were performed with K562 cells as well as normal 
and CML CD34+ cells treated with and without NIL. Densitometric quantification (normalized to 
internal control) is shown under the blots. (i) QPCR for mature, pri- and pre-miR-126 expression 
in K562 and CML CD34+ cells treated with and without NIL (n=3).  (j) IP with anti-RAN and 
immunoblotting with anti-SPRED1, Exp-5, RCC1 and RAN antibodies were performed with 
K562 cells with or without TKI washing-off. Densitometric quantification is shown under the 
blots. (k) QPCR for mature and pri-miR-126 expression (n=3), (l) miR-126 staining, and (m) 
mature and pre-miR-126 levels measured by Northern blotting in K562 cells. (n) SPRED1 was 
knocked down in K562 and CML CD34+ cells and protein lysates were pulled down by anti-RAN 
and immunoblotted with anti-Exp-5, RCC1 and RAN antibodies. Densitometric quantification 
(normalized to internal control) is shown under the blots.  (o) QPCR for mature, pri- and pre-
miR-126 expression (n=3) and (p) miR-126 staining in SPRED1 KD K562 cells. (q) QPCR for 
mature, pri- and pre-miR-126 expression (n=3) and (r) miR-126 staining in RAN KD K562 cells. 
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Figure 4: Endothelial cells in the niche supply miR-126 to normal and CML LTHSC 
(a) Gating strategy of EC (CD45-Ter119-CD31+), osteoblasts (OB, CD45-Ter119-CD31-
CD166+Sca-1-) and mesenchymal stem cells (MSC, CD45-Ter119-CD31-CD166-Sca-1+). (b) 
miR-126 expression by QPCR in LTHSC, EC, OB and MSC cells from normal and CML mice 
(n=5). EC were then sorted from the BM of SCLtTA/BCR-ABL mice and transduced with miR-
126 KD lentiviral vector (KD EC) or control vector (ctrl EC). CML LTHSC were sorted and co-
cultured with ctrl or KD EC or cultured alone (none) for 96h and (c) miR-126 expression (n=4), 
(d) cell cycling (n=3), (e) apoptosis (n=4), (f) cell growth (n=4) and (g) percentage of Flt3-
CD150+CD48- LSK cells (n=4) were measured. (h) Suspended (susp) and EC-attached (atta) 
sub-fractions of CML LTHSC were collected and miR-126 expression was measured by QPCR 
(n=3). CML LTHSC (CD45.2 B6) were sorted and co-cultured with ctrl or KD EC or none for 96h 
and then transplanted into recipient mice (CD45.1 B6, 1000 cells/mouse, n=8 each). (i) WBC 
and (j) CML donor cell engraftment in PB and (k) survival of recipient mice were monitored. (l) 
Representative flow cytometry plots of EC staining and (m) frequency of Sca-1+ cells in 
endosteal EC or central EC from normal and CML mice (n=3) and (n-o) miR-126 expression in 
endosteal EC or central EC (n=3) and in Sca-1+/- EC (n=3) from normal and CML mice by 
QPCR. (p) miR-126 expression by QPCR in endosteal LTHSC or central LTHSC from normal 
and CML mice (n=3). (q) Representative flow cytometry plots and (r-s) combined results of cell 
cycling (n=3) of endosteal LTHSC or central LTHSC from normal and CML mice.  
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Figure 5: Endothelial cells in the niche supply miR-126 to CML LTHSC 
 (a) Frequency of BM mononuclear cell subpopulations (n=5) and (b) LTHSC (n=5) in miR-
126(c-KO)/Mx1-cre+ (Mx1+) and miR-126(c-KO)/Mx1-cre- (Mx1-) mice at 16 weeks after pIpC 
injection to induce “cre” activation and miR-126 KD. (c) miR-126 expression in CML BM cells 
(n=4), (d) WBC and (e) survival of SCLtTA/BCR-ABL/miR-126(c-KO)/Mx1+/- mice subjected to 
tetracycline withdrawal to induce BCR-ABL expression and pIpC injection to induce miR-126 KD 
(n=9). (f) CD45.2 CML LTHSC (400 cells/mouse) from BCR-ABL-induced and pIpC-injected 
SCLtTA/BCR-ABL/miR-126(c-KO)/Mx1+ or Mx1- mice were transplanted into CD45.1 congenic 
recipient mice by tail vein injection (n=10 for each group). (g) miR-126 expression in donor CML 
LTHSC by QPCR (n=3), (h) WBC and (i) CML cell engraftment in PB and (j) survival of recipient 
mice were monitored (n=10). In order to track donor cells in CD45.2 miR-126(c-KO)/Tie2+/- 
recipient mice, CD45.2 SCLtTA/BCR-ABL B6 mice were crossed with CD45.1 B6 mice to 
generate CD45.1/CD45.2 SCLtTA/BCR-ABL mice. (k) CD45.1/CD45.2 CML LTHSC (400 
cells/mouse) from induced SCLtTA/BCR-ABL mice were transplanted into CD45.2 congenic 
miR-126(c-KO)/Tie2- (n=14), miR-126(c-KO)het/Tie2+ (n=10) and miR-126(c-KO)hom/Tie2+ 
recipient mice (n=8). (l) miR-126 expression in EC sorted from the miR-126(c-KO)/Tie2-, 
het/Tie2+ and hom/Tie2+ recipient mice by QPCR (n=3), (m) WBC and (n) CML cell 
engraftment in PB and (o) survival of recipient mice were monitored. (p) CD45.2 CML LTHSC 
(400 cells/mouse) from BCR-ABL-induced and pIpC-injected SCLtTA/BCR-ABL/miR-126(c-
KO)/Mx1+ or Mx1- mice were transplanted into CD45.2 miR-126(c-KO)het/Tie2+ or Tie2- 
recipient mice (n=12 for each group), respectively and (q) WBC and (r) survival of the recipient 
mice was monitored.  
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Figure 6: miR-126 knockdown enhanced TKI-mediated targeting of CML LSC 
CML Lin-CD34+CD38- cells were transduced with GFP-expressing miRZip anti-miR-126 (KD, 
MOI=20) or miR-126 precursor (OE, MOI=10) or control lentivirus (MOI=10-20). GFP+ cells were 
selected and treated with NIL (5µM) for 72h and then (a) miR-126 expression, (b) cell cycling, (c) 
apoptosis, (d) cell growth, (e) CFC and (f) CFC replating efficiency were measured (n=4). 
LTHSC from induced SCLtTA/BCR-ABL mice were transduced with miR-126 KD or miR-126 OE 
or control lentivirus (MOI=20). GFP+ cells were treated with NIL (5µM) for 72h and (g) miR-126 
expression, (h) cell cycling, (i) apoptosis, (j) cell growth and (k) CFC were measured (n=4). 
Human CML Lin-CD34+CD38- cells were transduced with miR-126 KD or control lentiviral vector. 
GFP+ cells were selected (5X105 cells/mouse, n=10 each) and treated with NIL (5µM) for 4 days 
and then transplanted into irradiated (300cGy) NSG-SGM3 mice. (l-m) Engraftment of human 
CD45+GFP+ cells in PB at 4 weeks (n=8) and in BM at 16 weeks (n=10) was measured. CML 
LTHSC from CD45.1/CD45.2 SCLtTA/BCR-ABL mice were transplanted into CD45.2 miR-
126(c-KO)het/Tie2+ or Tie2- mice (n=17 each). Upon confirming development of CML, the mice 
were treated with (n=7 each) or without NIL (n=10 each) for 3 weeks, (n) WBC and (o) CML 
donor cell engraftment and (p) survival were monitored. 
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Figure 7: CpG-miR-126 inhibitor enhances in vivo targeting of CML LSC in combination 
with Nilotinib 
Human CD34+ cells from CP CML patient samples were transplanted into irradiated NSG-SGM3 
mice (n=56). At 6 weeks after transplantation, the mice were randomly divided into 4 groups 
(n=14 each) and treated with scrRNA (5mg/kg, i.v. 4 times a week), inhibitor (5mg/kg i.v. 4 times 
a week), scrRNA + NIL (50mg/kg, daily by gavage), or inhibitor + NIL for 3 weeks. (a) Human 
CD45+, (b) CD45+CD34+CD38- HSC and (c) CD45+CD34+CD38-CD90+ LTHSC engraftment in 
BM was measured. CD45.2 BM cells from induced SCLtTA/BCR-ABL mice were transplanted 
into congenic CD45.1 B6 mice (n=40) to generate a cohort of mice with CML-like disease. 
Following confirmation of CML development at 4 weeks after transplantation, mice were 
randomly divided into 4 groups (n=10 each) and treated as above with scrRNA, inhibitor, 
scrRNA + NIL, or inhibitor + NIL for 3 weeks. Percentage of donor CML cells in (d) PB, (e) 
spleen and (f) BM, numbers of donor CML LSK in (g) spleen and (h) BM, and numbers of donor 
CML LTHSC in (i) spleen and (j) BM after 3 weeks’ treatment were measured. (k) Another 
cohort of mice was treated for 3 weeks and then followed for survival (n=10 in each group). BM 
cells (CD45.2) from treated leukemic mice (3 weeks) were pooled, and 4×106, 2×106, 1×106, 
and 5×105 cells/mouse were transplanted into secondary congenic CD45.1 recipient mice (n=6 
mice/dose/condition x 4 doses x 4 conditions = 96 mice). The recipient mice were monitored for 
16 weeks for CML cell engraftment in blood and leukemia development by WBC counts. (l) 
Frequency of leukemia initiating cells (LIC) was quantified using L-Calc software.  
